Genentech announced that the phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival.
Positive top-line data from the monotherapy arm of the ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO) demonstrated that Rubraca (rucaparib) as maintenance treatment achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with placebo.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is more than halfway to its recruiting goal of 128,905 participants, with more than 20% of participants in the United States being Black. Recruitment of women from diverse backgrounds is vital to ensuring that TMIST trial results will be applicable across races, ethnicities, and under-served communities.
In support of the reignited Cancer Moonshot’s goal of fostering data sharing in cancer research, the National Cancer Institute has launched the Molecular Characterization Initiative for pediatric tumors (The Cancer Letter, Feb. 4, 2022).
MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 CAR T-cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma.
A computational approach developed by researchers at MD Anderson Cancer Center combines data from parallel gene-expression profiling methods to create spatial maps of a given tissue at single-cell resolution. The resulting maps can provide insights into the cancer microenvironment and other tissue types.
An outreach program at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) is mailing free at-home colon cancer screening tests to Black primary care patients who have not yet had their routine colonoscopy.
A UPMC-led study suggests that healthcare professionals exposed to SARS-CoV-2 can safely return to work after seven days of quarantine if they are asymptomatic and receive a negative COVID-19 test. The findings, from the first reported study evaluating reduced quarantine duration in a healthcare setting, offer a potential new strategy for mitigating staffing shortages prior to a next wave of COVID-19 cases.
The NCI-MATCH trial offers treatment opportunities for adult patients with relapsed, refractory cancers. A new treatment arm (Z1M) is evaluating the immunotherapy combination of relatlimab and nivolumab in patients whose tumors have mismatch repair deficiency and LAG-3 expression and have progressed after anti–PD-1/PD-L1 immunotherapy.
A study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumor-killing effects of cisplatin in animal models.
